Our Pipeline
A growing pipeline of T-SIGn® therapeutics aiming to enable a patient’s immune system to recognize, attack, and clear solid tumors.
Akamis Bio has a growing pipeline of T-SIGn® therapeutics capable of driving the intratumoral expression of a broad range of therapeutic proteins, as well as immunologically active biomolecules which aim to enable a patient’s immune system to recognize, attack, and clear solid tumors.
With more than 200 patients treated across our clinical studies, T-SIGn® therapeutics have demonstrated a consistent safety & tolerability profile, as well as promising preliminary evidence of clinical activity.
Stage
NG-347
Three transgenes:
producing membrane bound CD80 and secreted MIP1α and IFNα
T-cell attraction
and activation
NG-796A
Three transgenes:
producing IL-12, IL-15 and a chemokine
T-cell and
NK Cell
activation
NG-XXX
Novel transgene combinations
Variety of mechanisms targeted
Product
Transgene
Payload
Principal
Mechanism
NG-350A
Two transgenes:
producing a secreted CD40 agonist monoclonal antibody
NG-641
Four transgenes:
producing an anti-FAP bispecific plus cytokines/ chemokines
CD40 Agonism
Phase 1
Phase 2
Phase 3
Research
IND
Enabling
Commercial Rights
Anti-
Stromal
NG-348
Two transgenes:
producing membrane bound anti-CD3 scFv antibody and CD80
Immune cell recruitment & activation
